Equities

DH Enchantment Inc

ENMI:PKC

DH Enchantment Inc

Actions
  • Price (USD)0.006
  • Today's Change0.00 / 0.00%
  • Shares traded100.00k
  • 1 Year change--
  • Beta5.6850
Data delayed at least 15 minutes, as of Oct 03 2024 20:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DH Enchantment, Inc. is a holding company. The Company conducts its operations through its Hong Kong subsidiary, Ho Shun Yi Limited (HSY). HSY is engaged primarily in the sale and distribution of COVID-19 rapid antigen tester sets. HSY is one of the authorized commercial distributors of the INDICAID COVID-19 Rapid Antigen Test in the Hong Kong market. The INDICAID COVID-19 Rapid Antigen Test is developed and manufactured in Hong Kong. The INDICAID product can provide a COVID-19 testing result in approximately 20 minutes. HSY’s main customers are distributors of personal hygiene products into the market.

  • Revenue in USD (TTM)100.00
  • Net income in USD-173.19k
  • Incorporated2004
  • Employees1.00
  • Location
    DH Enchantment Inc6228 DARTLE STREETLAS VEGAS 89130United StatesUSA
  • Phone+1 (508) 336-3552
  • Fax+1 (888) 452-8153
  • Websitehttp://wesaveenergy.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ENMI:PKC since
announced
Transaction
value
OLS Asia CorpAnnounced02 Apr 202402 Apr 2024Announced--20.00m
Data delayed at least 15 minutes, as of Oct 03 2024 20:52 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aytu Biopharma Inc81.00m-15.84m14.39m99.00--0.5043--0.1776-2.86-2.8614.634.640.63642.153.08818,202.00-12.45-27.76-25.70-46.0367.3958.88-19.56-56.450.7916-0.05940.3531---24.5861.737.08------
Cara Therapeutics Inc11.00m-111.08m14.60m55.00--1.26--1.33-2.04-2.040.20170.21150.10631.102.10199,927.30-107.38-35.76-132.61-40.8274.66---1,010.20-162.104.48--0.00---49.929.26-38.65--100.66--
Nexgel Inc5.01m-3.39m16.92m19.00--3.79--3.38-0.5722-0.57220.84640.65890.49423.036.44263,631.60-35.74-44.61-48.15-56.1923.745.02-72.33-180.980.8135--0.1992--99.6613.0633.48------
Cumberland Pharmaceuticals, Inc.37.79m-10.38m17.76m91.00--0.6735--0.47-0.7328-0.73282.671.870.45010.86433.17415,225.80-12.35-7.03-17.75-9.5282.5879.95-27.45-17.641.26-38.850.382---5.856.15-12.73---36.17--
TherapeuticsMD Inc996.00k-4.83m19.14m1.00--0.6918--19.22-0.4348-0.55380.08892.400.0212--0.5048996,000.00-10.31-53.35-13.13-111.6145.0886.67-485.34-236.57----0.00---98.14-39.53-816.85------
Tonix Pharmaceuticals Holding Corp12.46m-149.01m20.14m103.00--0.0336--1.62-110.99-110.996.164.280.10830.8436--120,951.50-129.55-59.46-157.22-65.9221.59---1,196.12-5,126.730.7181--0.1678------0.1874--320.57--
China Health Industries Holdings, Inc.95.95k-1.36m21.30m32.00------221.99-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
Cyclo Therapeutics Inc1.13m-20.74m21.52m8.00------19.00-0.9104-0.91040.0474-0.17850.2420.400213.16141,553.80-443.08-132.22---215.1791.5690.37-1,831.29-1,114.040.4283-------21.761.25-29.81---3.95--
BioXcel Therapeutics Inc2.40m-107.83m22.41m74.00------9.33-3.56-3.560.074-1.840.02340.59413.8732,472.97-104.93-74.57-150.29-84.0643.07---4,487.39-32,300.742.25-10.103.59--268.00---8.02---43.26--
DH Enchantment Inc100.00-173.19k22.99m1.00------229,878.60-0.0002-0.00020.00-0.00120.04380.1493--100.00-7,579.43------0.00---173,190.00--0.0029-14.85-----95.43--59.53------
KALA BIO Inc0.00-38.72m24.65m43.00--1.79-----13.95-13.950.002.980.00----0.00-60.45-57.83-78.16-69.32--57.06---1,553.61---11.360.7174---100.00--5.85---17.31--
Polypid Ltd0.00-24.70m24.90m59.00--10.61-----9.65-9.650.000.33370.00----0.00-107.89-76.92-164.39-89.61-----------24.210.8425------39.67---42.34--
Incannex Healthcare Inc12.00k-18.46m27.88m9.00--2.24--2,322.97-1.14-1.140.00070.70670.0003--0.00241,333.33-48.51-130.12-54.36-148.24-----153,833.30-3,421.98----0.00----61.0362.18--73.79--
Dare Bioscience Inc2.84m-7.20m28.20m23.00--10.56--9.93-1.07-1.070.35790.31260.1213--3.85123,462.20-30.76-109.51-191.39-246.260.8477---253.60-1,104.55----0.00---71.92--2.54--121.37--
Natural Alternatives International, Inc.113.80m-7.22m28.33m296.00--0.3431--0.2489-1.23-1.2319.3813.320.76763.969.52384,445.90-4.872.33-5.612.806.0314.24-6.342.061.59-10.210.13260.00-26.11-3.82-386.16---10.75--
Acasti Pharma Inc0.00-11.45m31.53m32.00--0.5312-----1.22-1.220.005.850.00-------16.04-31.68-16.57-33.95-------56,271.43---37.800.00------69.71---47.16--
Data as of Oct 03 2024. Currency figures normalised to DH Enchantment Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.